Leukemia & Lymphoma最新文献_第10页

A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma. CC-486、来那度胺、obinutuzumab治疗复发/难治性惰性非霍奇金淋巴瘤的I期临床试验

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2024-12-28 DOI: 10.1080/10428194.2024.2443552

Tamer Othman, Gabriel Marquez-Arreguin, Naseem Esteghamat, Joseph Tuscano

引用次数: 0

Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis. 鲁索利替尼早期干预可改善骨髓纤维化患者的脾反应。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-09 DOI: 10.1080/10428194.2024.2447884

Pankit Vachhani, Paola Guglielmelli, Jennifer Repp, J E Hamer-Maansson, Evan Braunstein, Haifa Kathrin Al-Ali

引用次数: 0

Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review. 高负荷滤泡性淋巴瘤治疗进展综述。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-05 DOI: 10.1080/10428194.2024.2447371

Efrat Luttwak, Anita Kumar, Gilles Salles

引用次数: 0

gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles. gneSeqCOO：一种基于肿瘤整体RNA测序谱的弥漫性大b细胞淋巴瘤细胞起源分类的新方法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-10 DOI: 10.1080/10428194.2024.2446613

Will Harris, Yi Cao, Franck Morschhauser, Gilles Salles, Yanwen Jiang, Alessia Bottos, Georg Lenz, Christopher R Bolen

{"title":"gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles.","authors":"Will Harris, Yi Cao, Franck Morschhauser, Gilles Salles, Yanwen Jiang, Alessia Bottos, Georg Lenz, Christopher R Bolen","doi":"10.1080/10428194.2024.2446613","DOIUrl":"10.1080/10428194.2024.2446613","url":null,"abstract":"The cell of origin (COO) classification is an expression-based tumor algorithm identifying molecular subtypes of diffuse large B-cell lymphoma (DLBCL) with distinct prognostic characteristics. Traditional immunohistochemical methods for classifying COO subtypes have poor concordance and limited prognostic value in frontline DLBCL. In contrast, RNA-based metrics like the NanoString Lymphoma Subtyping Test (LST) define more robust subtypes with validated prognostic associations. This study introduces gneSeqCOO, an algorithm using bulk RNA Sequencing (RNASeq) profiles of individual tumor biopsies for COO classification based on a fixed reference. This method produced consistent per-sample results and was robust to variation in RNA quality and sequencing bias. Validation in >1000 DLBCL samples showed high concordance with the NanoString LST assay, even in cohorts containing only one COO subtype. gneSeqCOO presents a robust and versatile alternative to existing assays, potentially reducing the need for additional samples where RNASeq was already generated. The package is available at https://github.com/Genentech/gneSeqCOO.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"898-905"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142962026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma. 依鲁替尼治疗先前未治疗的高风险阴燃套细胞淋巴瘤的2期试验。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-21 DOI: 10.1080/10428194.2025.2454540

Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee, Luis Fayad, Lei Feng, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Wendy Chen, Guofan Xu, Anita Deswal, Cezar Iliescu, Maria Badillo, Michelle Ky, Michelle Avellaneda, Guilin Tangc, L Jeffrey Medeiros, Francisco Vega, Christopher R Flowers, Michael L Wang

引用次数: 0

Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD. 中期pet预测先期brentuximab vedotin-AVD治疗的IV期霍奇金淋巴瘤的无进展生存期。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-11 DOI: 10.1080/10428194.2024.2446609

Chiara Rusconi, Angelica Barone, Andrea Visentin, Benedetta Bianchi, Vittorio Ruggero Zilioli, Andrea Bernardelli, Sara Iadecola, Edoardo Olivari, Francesca Gaia Rossi, Manuel Gotti, Caterina Cecchetti, Benedetta Puccini, Silvia Franceschetti, Alfredo Molteni, Sara Steffanoni, Fabrizio Marino, Anna Vanazzi, Anna Guidetti, Michele Merli, Federico Mazzon, Alfredo Marchetti, Alessandro Cellini, Cristina Muzi, Rosalba Miceli, Carlo Visco, Alessandro Re, Paolo Corradini

{"title":"Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD.","authors":"Chiara Rusconi, Angelica Barone, Andrea Visentin, Benedetta Bianchi, Vittorio Ruggero Zilioli, Andrea Bernardelli, Sara Iadecola, Edoardo Olivari, Francesca Gaia Rossi, Manuel Gotti, Caterina Cecchetti, Benedetta Puccini, Silvia Franceschetti, Alfredo Molteni, Sara Steffanoni, Fabrizio Marino, Anna Vanazzi, Anna Guidetti, Michele Merli, Federico Mazzon, Alfredo Marchetti, Alessandro Cellini, Cristina Muzi, Rosalba Miceli, Carlo Visco, Alessandro Re, Paolo Corradini","doi":"10.1080/10428194.2024.2446609","DOIUrl":"10.1080/10428194.2024.2446609","url":null,"abstract":"Brentuximab vedotin (BV) plus doxorubicin, vinblastine and dacarbazine (AVD) demonstrated to improve survival compared to ABVD as frontline treatment of advanced stage Hodgkin Lymphoma (HL). We retrospectively collected data of 99 stage IV HL patients treated off-protocol with BV-AVD to evaluate the predictive role of interim-PET. Median age was 36 years (range: 18-82); 83.8% patients completed all planned 6 cycles and 80.8% obtained complete response at PET6. Median follow-up was 14.4 months; 1-year progression-free survival (PFS) and overall survival were 84.1% (CI 95%: 77-91.9) and 96.9% (CI 95%: 93.6-100). PET2-negative patients had a superior 1-year PFS compared to PET2-positive patients: 90.0% vs 46.2% (p < .001). At multivariable analysis, PET2 positivity retained unfavorable statistical significance in PFS: HR 4.6 (95% CI: 1.4-15.2, p = .009). BV-AVD was confirmed to be effective in a real-world setting, while PET2-positive patients displayed a remarkably lower 1-year PFS than that previously reported and might benefit from a PET-driven approach.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"879-887"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study. 具有心血管危险因素的经典霍奇金淋巴瘤患者的PBVD治疗方案（聚乙二醇化脂质体阿霉素、博来霉素、长春新碱、达卡巴嗪）：一项回顾性研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-05 DOI: 10.1080/10428194.2024.2447888

Jia Jin, Dan-Dan Meng, Yu Wen, Qun-Ling Zhang, Fang-Fang Lv, Guang-Liang Chen, Xue-Jun Ma, Bao-Hua Yu, Sheng-Jian Zhang, Chang Liu, Zu-Guang Xia

{"title":"PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.","authors":"Jia Jin, Dan-Dan Meng, Yu Wen, Qun-Ling Zhang, Fang-Fang Lv, Guang-Liang Chen, Xue-Jun Ma, Bao-Hua Yu, Sheng-Jian Zhang, Chang Liu, Zu-Guang Xia","doi":"10.1080/10428194.2024.2447888","DOIUrl":"10.1080/10428194.2024.2447888","url":null,"abstract":"This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV. Among them, 56 (66.7%) received radiotherapy (45 with stage I-II and 11 with stage III-IV disease). Seventy-four (88.1%) patients achieved complete response. At a median follow-up of 49.7 months, 2- and 5-year progression-free survival were both 83.2%, and overall survival was 98.7% and 94.9%. Adverse events occurred in 73.8% of patients, including 7.1% cardiac events. No treatment-related deaths were observed. This approach showed a favorable benefit-to-risk profile in this population.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"888-897"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm. 口服地西他滨-cedazuridine联合venetoclax治疗母细胞浆细胞样树突状细胞肿瘤病例系列。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-30 DOI: 10.1080/10428194.2025.2498046

Hannah Goulart, Guillermo Garcia-Manero, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Farhad Ravandi, Muzaffar Qazilbash, Caitlin Rausch, Gabriela Llaurador Caraballo, Sherry Pierce, Naveen Pemmaraju

引用次数: 0

CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD^mut-AML): a flow-cytometric marker for an accurate diagnostic workup. CD99在FLT3内部串联重复的急性髓系白血病（FLT3- itdmut - aml）中的表达：一种用于准确诊断的流式细胞术标记

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-28 DOI: 10.1080/10428194.2025.2497392

Alessandro Laganà, Deborah Kasmi, Daniela Diverio, Maria Laura Bisegna, Ida Carmosino, Emilia Scalzulli, Clara Minotti, Maria Laura Milani, Sonia Buffolino, Maurizio Martelli, Massimo Breccia, Maria Stefania De Propris

{"title":"CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut-AML): a flow-cytometric marker for an accurate diagnostic workup.","authors":"Alessandro Laganà, Deborah Kasmi, Daniela Diverio, Maria Laura Bisegna, Ida Carmosino, Emilia Scalzulli, Clara Minotti, Maria Laura Milani, Sonia Buffolino, Maurizio Martelli, Massimo Breccia, Maria Stefania De Propris","doi":"10.1080/10428194.2025.2497392","DOIUrl":"https://doi.org/10.1080/10428194.2025.2497392","url":null,"abstract":"Internal tandem duplications of FLT3 (FLT3-ITD) in acute myeloid leukemia (AML) are associated with poor outcomes. CD99 is frequently overexpressed in AML and emerged as potential diagnostic marker. Ninety consecutive newly diagnosed AML patients were retrospectively analyzed. Immunophenotypic profiles were correlated with molecular assessment. Patients were categorized into FLT3-ITDmut (28.9%) and FLT3wt (71.1%). CD99 was expressed in 100% of FLT3-ITDmut-AML compared to 48% in FLT3wt cases. FLT3-ITDmut-AML exhibited higher CD99 expression percentage. CD34 expression was lower in FLT3-ITDmut-AML, with a positivity rate of 31% versus 83% in FLT3wt cases. Multivariate analysis confirmed that CD99 positivity (OR 17.67; p = 0.010) and CD34 negativity (OR 10.00; p = 0.039) were independently associated with FLT3-ITDmut-AML. CD99 and CD34 displayed NPVs of 100% and 86.9%, respectively, with moderate PPVs (45.6% and 62.1%) for the diagnosis of FLT3-ITDmut-AML. CD99 is a highly reliable marker in FLT3-ITDmut-AML and its absence virtually excludes the presence of a FLT3-ITD mutation.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). 髓系恶性肿瘤和肿瘤疾病协会（COMMAND）的研究结果表明，门诊低甲基化药物和venetoclax治疗新诊断的急性髓系白血病的可行性和安全性，有或没有增加。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-28 DOI: 10.1080/10428194.2025.2496339

Rory M Shallis, Julian J Weiss, Eric S Winer, Talha Badar, Alok Swaroop, Peter Doukas, Emily Geramita, Henry Le, Sonal Agarwal, Man Yee Merl, Yasmin Abaza, Annie Im, Mark R Litzow, Nikolai A Podoltsev

引用次数: 0